Germany’s ambitious experiment with cannabis legalization is facing unexpected challenges, as new data reveals 250,000 residents now grapple with addiction, and the illicit drug market flourishes. The government’s efforts to regulate and legalize cannabis were intended to reduce criminal activity and improve public safety, but have inadvertently fueled a surge in black market activities. Critics argue that the regulatory framework lacks adequate provisions to prevent addiction, contributing to an alarming rise in substance abuse. The unforeseen increase in illegal drug trade signals the policy’s shortcomings in supplanting unregulated channels, resulting in growing public concern and calls for policy revision. As Germany reassesses its cannabis laws, the nation faces a critical juncture in addressing this complex issue that intertwines public health, safety, and economic factors. This situation underscores the intricate balance required in drug policy reform, highlighting lessons for other countries considering similar moves.
The Korea TimesNew data shows CLYM116 reduces key IgA nephropathy biomarkers by ~70%, supporting a 12-week dosing regimen
New data released by CLIMB Bio and MabWorks reveals that their investigational drug CLYM116 significantly reduces critical biomarkers associated with IgA nephropathy by approximately 70%.